Interview with Mark Frasier: a Michael J Fox Foundation perspective on precision medicine in Parkinson's.
This interview was conducted by Lauren Pulling, Editor of Neurology Central. The full interview can be accessed on Neurology Central as part of the NCTalks podcast series which is available at: www.neurology-central.com/2016/11/28/nctalks-mark-frasier-precision-medicine-parkinsons-disease Mark Frasier co-manages a team of research professionals who stay closely linked to the Parkinson's research community in order to develop an aggressive and innovative agenda for accelerating research and drug development for Parkinson's disease. He also supports the foundation's priority interest in developing biomarkers for Parkinson's disease that will accelerate clinical trials of new drugs. He earned an undergraduate degree in biochemistry from the University of Dayton and a PhD in pharmacology from Loyola University Chicago. He completed his postdoctoral work in the Neuroscience Discovery Research Group at Eli Lilly, Inc., in Indianapolis, Indiana, where he worked on drug discovery research in Parkinson's and Alzheimer's disease. He joined the Michael J. Fox Foundation in 2006 and is now Senior Vice President of Research Programs.